Valeo Pharma Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Al Moghaddam

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.3yrs
Gemiddelde ambtstermijn bestuur	1.8yrs

Recente managementupdates

Recent updates

Market Might Still Lack Some Conviction On Valeo Pharma Inc. (TSE:VPH) Even After 55% Share Price Boost

Jun 14

Market Cool On Valeo Pharma Inc.'s (TSE:VPH) Revenues Pushing Shares 31% Lower

Apr 20

Valeo Pharma Inc. (TSE:VPH) Stocks Pounded By 33% But Not Lagging Industry On Growth Or Pricing

Mar 02

Investors Still Aren't Entirely Convinced By Valeo Pharma Inc.'s (TSE:VPH) Revenues Despite 68% Price Jump

Jan 17

Valeo Pharma Inc. (TSE:VPH) Might Not Be As Mispriced As It Looks After Plunging 29%

Jun 08

Analysts Have Just Cut Their Valeo Pharma Inc. (TSE:VPH) Revenue Estimates By 24%

Jun 24

Earnings Update: Valeo Pharma Inc. (TSE:VPH) Just Reported And Analysts Are Trimming Their Forecasts

Jun 17

Have Insiders Been Buying Valeo Pharma Inc. (CSE:VPH) Shares This Year?

Feb 08

CEO

Al Moghaddam (57 yo)

less than a year

Tenure

Mr. Al Moghaddam, B. Com. CMA had been a Director at Valeo Pharma Inc. since March 21, 2024 until June 2024 and served as its Chief Development Officer since June 2024 until August 2024 and serves as its C...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kyle Steiger	Senior VP & Chief Commercial Officer	2.3yrs	CA$388.21k	0.020% CA$ 872.5
Al Moghaddam	Chief Executive Officer	less than a year	geen gegevens	geen gegevens
Pascal Tougas	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Frederic Dumais	Director of Communications & Investor Relations	3.8yrs	geen gegevens	geen gegevens
Guy-Paul Allard	VP of Legal Affairs & Corporate Secretary	no data	geen gegevens	0.41% CA$ 18.0k
Jean Fournier	Head of Ophthalmology Business Unit	2.3yrs	geen gegevens	geen gegevens

2.3yrs

Gemiddelde duur

Ervaren management: Het managementteam van VPH wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Robert Raich	Independent Director	less than a year	geen gegevens	0.18% CA$ 7.9k
Richard MacKay	Chairman of the Advisory Board & Director	15.8yrs	geen gegevens	16.44% CA$ 730.0k
Steven Saviuk	Chairman	21.7yrs	CA$466.29k	0.18% CA$ 8.1k
Marc Leger	Independent Non-Executive Director	2.6yrs	geen gegevens	2.36% CA$ 104.9k
Richard Lajoie	Independent Director	less than a year	geen gegevens	geen gegevens
Charles Bisaillon	Independent Director	less than a year	geen gegevens	geen gegevens

1.8yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van VPH wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw bestuur.

Valeo Pharma Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Valeo Pharma Inc. Announces Board Changes

Valeo Pharma Inc. Appoints Al Moghaddam as Chief Development Officer and Consequently Steps Down from its Board of Directors

Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors

Valeo Pharma Inc., Annual General Meeting, Apr 25, 2024

Valeo Pharma Inc. Announces Board Changes

Valeo Pharma Inc. Announces Chief Financial Officer Changes

Recent updates

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target decreased by 20% to CA$0.40

Valeo Pharma Inc. to Report Q3, 2024 Results on Sep 12, 2024

Valeo Pharma Inc. Announces Board Changes

Valeo Pharma Inc. Appoints Al Moghaddam as Chief Development Officer and Consequently Steps Down from its Board of Directors

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Market Might Still Lack Some Conviction On Valeo Pharma Inc. (TSE:VPH) Even After 55% Share Price Boost

Valeo Pharma Inc. to Report Q2, 2024 Results on Jun 13, 2024

Market Cool On Valeo Pharma Inc.'s (TSE:VPH) Revenues Pushing Shares 31% Lower

New major risk - Market cap size

Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors

First quarter 2024 earnings released

New major risk - Revenue and earnings growth

Valeo Pharma Inc. to Report Q1, 2024 Results on Mar 14, 2024

Valeo Pharma Inc. (TSE:VPH) Stocks Pounded By 33% But Not Lagging Industry On Growth Or Pricing

Valeo Pharma Inc., Annual General Meeting, Apr 25, 2024

Valeo Pharma Inc. Announces Board Changes

Price target decreased by 12% to CA$0.72

Consensus revenue estimates fall by 14%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Valeo Pharma Inc. to Report Q4, 2023 Results on Jan 29, 2024

Investors Still Aren't Entirely Convinced By Valeo Pharma Inc.'s (TSE:VPH) Revenues Despite 68% Price Jump

New minor risk - Share price stability

Valeo Pharma Inc. Announces Chief Financial Officer Changes

Valeo Pharma Inc. Announces Appointment of Mr. Richard Lajoie to Board of Directors

New major risk - Market cap size

New minor risk - Profitability

Consensus EPS estimates fall by 23%

Price target decreased by 16% to CA$1.23

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Valeo Pharma Inc. to Report Q3, 2023 Results on Sep 13, 2023

Valeo Pharma Inc. announced that it has received CAD 4.499999 million in funding from Investissement Québec

Consensus EPS estimates upgraded to CA$0.18 loss

Less than half of directors are independent

Valeo Pharma Inc. Announces Board Appointments

Forecast breakeven date pushed back to 2025

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Valeo Pharma Inc. to Report Q2, 2023 Results on Jun 13, 2023

Valeo Pharma Inc. (TSE:VPH) Might Not Be As Mispriced As It Looks After Plunging 29%

First quarter 2023 earnings: EPS misses analyst expectations

Independent Director exercised options to buy CA$151k worth of stock.

Valeo Pharma Obtains Public Reimbursement for Onstryv in Quebec

Consensus EPS estimates fall by 31%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Valeo Pharma Announces Filing of New Drug Submission-Covid 19 with Health Canada for Sabizabulin for the Treatment of Hospitalized Covid-19 Patients

Valeo Pharma Inc. to Report Q4, 2022 Results on Jan 30, 2023

Valeo Pharma Inc. Announces Stepping Down of Frederic Fasano as President and Chief Operating Officer

Valeo Pharma Inc. Revises Revenue Guidance for the Fourth Quarter of 2022

Price target increased to CA$1.63

Less than half of directors are independent

Valeo Pharma Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Third quarter 2022 earnings: EPS misses analyst expectations

Valeo Pharma Inc. to Report Q3, 2022 Results on Sep 13, 2022

Valeo Pharma Announces Executive Appointments

Analysts Have Just Cut Their Valeo Pharma Inc. (TSE:VPH) Revenue Estimates By 24%

Consensus revenue estimates fall by 24%

Key Executive recently bought CA$113k worth of stock

Earnings Update: Valeo Pharma Inc. (TSE:VPH) Just Reported And Analysts Are Trimming Their Forecasts

No longer forecast to breakeven

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Valeo Pharma Inc. to Report Q2, 2022 Results on Jun 14, 2022

Less than half of directors are independent

Price target decreased to CA$1.70

Consensus EPS estimates fall by 42%

Key Executive exercised options to buy CA$1.5m worth of stock.

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Valeo Pharma Inc., Annual General Meeting, Apr 27, 2022

Valeo Pharma Inc. to Report Q4, 2021 Results on Feb 28, 2022